Cystic Fibrosis

Department of Health and Social Care written question – answered on 11th June 2018.

Alert me about debates like this

Photo of Ivan Lewis Ivan Lewis Independent, Bury South

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of NHS England taking a portfolio approach to its evaluation of the cost-effectiveness of cystic fibrosis medicines.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The Department has made no assessment. Negotiations between NHS England and Vertex on Orkambi continue, and the final decision on any arrangement lies with NHS England, and not the Government. The Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) and I wrote to Vertex in April following a Westminster Hall debate to encourage the company to work with NHS England on a proposal that represents value to the National Health Service and the taxpayer.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.